"Carcinoid Syndrome- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided which includes the disease overview and Carcinoid Syndrome treatment guidelines. The assessment part of the report embraces, in depth Carcinoid Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Carcinoid Syndrome Understanding
Carcinoid syndrome occurs when a rare cancerous tumor called a carcinoid tumor secretes certain chemicals into your bloodstream, causing a variety of signs and symptoms. Carcinoid tumors occur most commonly in the gastrointestinal tract or lungs, including stomach, small intestine, appendix, colon and rectum. Carcinoid syndrome typically occurs in people who have carcinoid tumors that are advanced. Treatment for carcinoid syndrome usually involves treating the cancer. The symptoms of carcinoid syndrome include episodes of warmth and redness of the face, head and upper chest; diarrhea; marked changes in blood pressure (usually hypotension, a decrease in blood pressure); asthmatic-like wheezing; weight loss or gain; malnutrition; dehydration; weakness; muscle and joint aching; and peptic ulcer. When tumors affect organs other than the gastrointestinal tract, such as the ovaries, carcinoid syndrome can occur in the absence of liver metastases.
Carcinoid Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Carcinoid Syndrome targeted therapeutics development with respective active and dormant or discontinued projects. Carcinoid Syndrome pipeline report covers 12+ companies. Some of the key players include Aquestive Therapeutics (AQST-305), QLT USA (Atrigel-Octreotide), Mateon Therapeutics (Fosbretabulin), etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Carcinoid Syndrome Analytical Perspective by DelveInsight
• In-depth Carcinoid Syndrome Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Carcinoid Syndrome Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Carcinoid Syndrome report provides an overview of therapeutic pipeline activity for Carcinoid Syndrome across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Carcinoid Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Carcinoid Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Carcinoid Syndrome
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Carcinoid Syndrome to formulate effective R&D strategies
• Assess challenges and opportunities that influence Carcinoid Syndrome R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Carcinoid Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Carcinoid Syndrome to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs